These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 15466204)
1. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Zhang X; Jin TG; Yang H; DeWolf WC; Khosravi-Far R; Olumi AF Cancer Res; 2004 Oct; 64(19):7086-91. PubMed ID: 15466204 [TBL] [Abstract][Full Text] [Related]
2. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419 [TBL] [Abstract][Full Text] [Related]
3. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850 [TBL] [Abstract][Full Text] [Related]
4. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127 [TBL] [Abstract][Full Text] [Related]
5. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339 [TBL] [Abstract][Full Text] [Related]
6. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells. Zhang X; Li W; Olumi AF Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199 [TBL] [Abstract][Full Text] [Related]
7. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Hernandez A; Thomas R; Smith F; Sandberg J; Kim S; Chung DH; Evers BM Surgery; 2001 Aug; 130(2):265-72. PubMed ID: 11490359 [TBL] [Abstract][Full Text] [Related]
8. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Kang J; Bu J; Hao Y; Chen F Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917 [TBL] [Abstract][Full Text] [Related]
9. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Mori T; Doi R; Toyoda E; Koizumi M; Ito D; Kami K; Kida A; Masui T; Kawaguchi Y; Fujimoto K Surgery; 2005 Jul; 138(1):71-7. PubMed ID: 16003319 [TBL] [Abstract][Full Text] [Related]
11. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Voelkel-Johnson C; King DL; Norris JS Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034 [TBL] [Abstract][Full Text] [Related]
12. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis. Kontny HU; Hämmerle K; Klein R; Shayan P; Mackall CL; Niemeyer CM Cell Death Differ; 2001 May; 8(5):506-14. PubMed ID: 11423911 [TBL] [Abstract][Full Text] [Related]
13. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Kazhdan I; Marciniak RA Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201 [TBL] [Abstract][Full Text] [Related]
15. Persistent inhibition of FLIP(L) expression by lentiviral small hairpin RNA delivery restores death-receptor-induced apoptosis in neuroblastoma cells. Flahaut M; Mühlethaler-Mottet A; Auderset K; Bourloud KB; Meier R; Popovic MB; Joseph JM; Gross N Apoptosis; 2006 Feb; 11(2):255-63. PubMed ID: 16502263 [TBL] [Abstract][Full Text] [Related]
16. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells. Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158 [TBL] [Abstract][Full Text] [Related]
17. Overcoming resistance to trail-induced apoptosis in prostate cancer by regulation of c-FLIP. Zhang X; Li W; Olumi AF Methods Enzymol; 2008; 446():333-49. PubMed ID: 18603132 [TBL] [Abstract][Full Text] [Related]
18. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639 [TBL] [Abstract][Full Text] [Related]
19. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Chawla-Sarkar M; Bae SI; Reu FJ; Jacobs BS; Lindner DJ; Borden EC Cell Death Differ; 2004 Aug; 11(8):915-23. PubMed ID: 15118763 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. MacFarlane M; Harper N; Snowden RT; Dyer MJ; Barnett GA; Pringle JH; Cohen GM Oncogene; 2002 Oct; 21(44):6809-18. PubMed ID: 12360407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]